Accumulate Zydus Lifesciences; target of Rs 1191: Prabhudas Lilladher

Moneycontrol • 1 day ago

Original source

Key Investment Pillars

  • Zydus Lifesciences has managed the transition of gRevlimid sales decline with new niche launches, and is working on a robust pipeline of complex products.
  • The company expects US sales to grow at 10% CAGR over FY26-28E, driven by base business volume growth and scale up of specialty portfolio.
  • Management has guided for 2-3 high value launches over FY27E/28E, and timely launch will be key to sustaining momentum in US sales.
  • The company has a strong pipeline of products, including injectables, 505(b)2, transdermals, NCE, biosimilars, and vaccines, which are expected to materialize over the next 2-3 years.

Thesis Validation Checklist

  • Investors should watch for the company's ability to sustain growth in US sales, driven by new launches and base business volume growth.
  • The company's pipeline of complex products and its ability to execute on high value launches will be key to driving growth.
  • Margin expansion will be important to monitor, given the higher opex and potential impact on profitability.
  • The company's debt levels and ability to manage its balance sheet will also be important to watch.